Archives
-
Exo1 Workflows for Membrane Trafficking Studies
2026-09-15
Exo1 enables acute, mechanistically distinct inhibition of Golgi-to-ER traffic for exocytosis assays, ARF1 studies, and controlled extracellular-vesicle experiments. This guide connects Exo1-based perturbation with the tumor-EV tracing strategy reported in Nature Cancer while clearly separating established product properties from practical assay recommendations.
-
CD44 Metabolic Rewiring in IDH-Mutant Leukemia
2026-09-15
The reference study identifies CD44 as a metabolic dependency of IDH-mutant leukemia, linking altered adhesion signaling to pentose phosphate pathway activity, NADPH production, and sustained R-2-hydroxyglutarate synthesis. Its isogenic genetic models and combination-treatment experiments suggest that CD44-mediated metabolic rewiring may complement direct mutant IDH inhibition in efforts to address resistance.
-
Lipidated Nanophotosensitizer Blocks Tumor EVs
2026-09-14
The reference study introduces a lipidated nanophotosensitizer that simultaneously accumulates in tumor cells and tumor extracellular vesicles (TEVs), enabling photodynamic suppression of primary tumors while disrupting prometastatic communication. Its dual-localization strategy offers a selective framework for linking tumor-cell treatment with extracellular-vesicle control, although translation beyond preclinical mouse models remains to be established.
-
Parathyroid hormone (1-34) (human) in Assays
2026-09-14
Learn how Parathyroid hormone (1-34) (human), SKU A1129, can support controlled cAMP, receptor, bone, kidney, viability, and proliferation experiments. This scenario-based guide covers dose selection, vehicle controls, peptide handling, assay interpretation, and practical vendor evaluation.
-
Exo1: A Mechanistic Lens on TEV Trafficking
2026-09-13
Exo1 provides a mechanistically distinct way to interrogate Golgi–ER membrane traffic, ARF1 behavior, and secretion-dependent tumor extracellular vesicle biology. This article connects Exo1 exocytic pathway research with translational questions in metastasis while clearly separating validated evidence from future hypotheses.
-
Lipidated Nanophotosensitizer Blocks Tumor EV Metastasis
2026-09-12
This study developed palmitic acid-displayed nanoparticles that simultaneously localize within tumor cells and tumor extracellular vesicles (TEVs), enabling near-infrared photodynamic treatment of both compartments. The findings show how coupling TEV tracing with intracellular and intra-vesicular reactive oxygen species generation can suppress primary tumor growth while disrupting prometastatic communication in multiple mouse models.
-
FITC-Concanavalin A (ConA) Conjugate Guide
2026-09-11
FITC-Concanavalin A (ConA) Conjugate is a direct fluorescent lectin probe for visualizing accessible α-D-glucose- and α-D-mannose-containing structures in cells and tissue samples. It supports cell surface carbohydrate detection, immunofluorescence staining, and flow cytometry, but it should not be used as a universal glycan stain or as evidence for a specific glycoprotein without additional validation.
-
FITC-Concanavalin A (ConA) Conjugate Guide
2026-09-11
FITC-Concanavalin A (ConA) Conjugate provides a fluorescent lectin probe for detecting α-D-glucose- and α-D-mannose-containing structures in cell and tissue samples. It is intended for carbohydrate-focused immunofluorescence and flow cytometry workflows, not for non-carbohydrate targets or use outside the specified storage conditions.
-
Aligned Ce6–Silk Fibroin Films for Infected Wounds
2026-09-10
The reference study developed an aligned silk fibroin electrospun film containing conjugated Chlorin e6 (Ce6) for near-infrared photodynamic treatment of Staphylococcus aureus-infected wounds. The composite combined contact guidance, mechanical integrity, hemocompatibility, reactive oxygen species generation, rapid antibacterial activity, and later-stage macrophage M2 polarization in an integrated wound-healing scaffold.
-
ZCL278: A Selective Cdc42 Inhibitor Workflow
2026-09-10
ZCL278 connects biochemical Cdc42 inhibition with measurable changes in migration, Golgi organization, neuronal branching, and growth cone dynamics. This workflow shows how to separate direct target engagement from downstream phenotypes while using kidney-fibrosis findings to design, not overstate, new translational experiments.
-
M344: From Chromatin Control to Translational Insight
2026-09-09
A thought-leadership perspective on how M344 connects HDAC biology with cancer-model validation, assay strategy, and carefully bounded translational opportunities.
-
Exo1 and the Secretory Logic of Tumor EVs
2026-09-09
Exo1 offers translational researchers a mechanistically distinct way to interrogate Golgi–ER traffic, ARF1 membrane association, and exocytic pathway contributions to tumor extracellular vesicle biology. This thought-leadership analysis connects Exo1’s cellular pharmacology with recent evidence that disabling tumor EV communication can inhibit metastasis, while clearly separating experimental opportunity from therapeutic proof.
-
Sulfamonomethoxine: From DHPS to Translation
2026-09-08
A translational framework for using Sulfamonomethoxine in veterinary, aquaculture, antimicrobial-resistance, and environmental studies while connecting DHPS biology, assay design, pharmacokinetic thinking, and ecological risk.
-
Fosinopril Sodium Workflows for ACE Research
2026-09-08
Fosinopril sodium connects nanomolar ACE inhibition with practical blood pressure, cardiac, and renal readouts. This guide covers solution handling, prodrug-aware assay design, pharmacokinetic sampling, and troubleshooting for reproducible hypertension research.
-
Protease Inhibitor Cocktail EDTA-Free: K1010 Guide
2026-09-07
K1010 limits endogenous proteolysis during protein extraction and sample preparation while avoiding EDTA, which is useful for workflows affected by divalent-cation chelation. It is suitable for lysates, Western blotting, co-immunoprecipitation, pull-downs, and selected phosphorylation or kinase assays, but DMSO compatibility and the need for rapid cold processing should be validated for each assay.